These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24818338)

  • 21. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
    Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
    Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
    Seck TL; Engel SS; Williams-Herman DE; Sisk CM; Golm GT; Wang H; Kaufman KD; Goldstein BJ
    Diabetes Res Clin Pract; 2011 Jul; 93(1):e15-7. PubMed ID: 21477878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
    Herman GA; Mistry GC; Yi B; Bergman AJ; Wang AQ; Zeng W; Chen L; Snyder K; Ruckle JL; Larson PJ; Davies MJ; Langdon RB; Gottesdiener KM; Wagner JA
    Br J Clin Pharmacol; 2011 Mar; 71(3):429-36. PubMed ID: 21284702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
    Ahrén B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K;
    Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
    Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
    Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
    Matthaei S
    MMW Fortschr Med; 2009 Oct; 151(42):54. PubMed ID: 19938786
    [No Abstract]   [Full Text] [Related]  

  • 32. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
    Thayer S; Chow W; Korrer S; Aguilar R
    Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
    Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
    Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
    Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
    Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Yang W; Guan Y; Shentu Y; Li Z; Johnson-Levonas AO; Engel SS; Kaufman KD; Goldstein BJ; Alba M
    J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

  • 39. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
    Yokota K; Igaki N
    Intern Med; 2012; 51(15):2041-4. PubMed ID: 22864134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sitagliptin (Januvia) for type 2 diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.